ADD CONDITION
Potassium citrate
Last content change checked dailysee data sync status
- Active ingredient
- Potassium Citrate 10 meq
- Other brand names
- Potassium Citrate (by Actavis Pharma, Inc.)
- Potassium Citrate (by Ani Pharmaceuticals, Inc.)
- Potassium Citrate (by Ascent Pharmaceuticals Inc)
- Potassium Citrate (by Biocomp Pharma, Inc.)
- Potassium Citrate (by Camber Pharmaceuticals, Inc)
- Potassium Citrate (by Remedyrepack Inc.)
- Potassium Citrate (by Rising Pharma Holdings, Inc.)
- Potassium Citrate (by Strides Pharma Inc.)
- Potassium Citrate (by Upsher-Smith Laboratories, Llc)
- Potassium Citrate (by Xlcare Pharmaceuticals, Inc.)
- Potassium Citrate (by Zydus Lifesciences Limited)
- Potassium Citrate (by Zydus Pharmaceuticals (usa) Inc.)
- Potassium-Cit (by Eywa Pharma Inc)
- Urocit-K (by Mission Pharmacal Company)
- View full label-group details →
- Drug classes
- Anti-coagulant, Calculi Dissolution Agent
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- Prescription status
- Rx (prescription)
- Pregnancy
- See Pregnancy Use Section
- Lactation
- See Lactation Use Section
- Marketed in the U.S.
- Since 2025
- Label revision date
- September 12, 2025
- FDA Insert
- Prescribing information, PDF file
- Active ingredient
- Potassium Citrate 10 meq
- Other brand names
- Potassium Citrate (by Actavis Pharma, Inc.)
- Potassium Citrate (by Ani Pharmaceuticals, Inc.)
- Potassium Citrate (by Ascent Pharmaceuticals Inc)
- Potassium Citrate (by Biocomp Pharma, Inc.)
- Potassium Citrate (by Camber Pharmaceuticals, Inc)
- Potassium Citrate (by Remedyrepack Inc.)
- Potassium Citrate (by Rising Pharma Holdings, Inc.)
- Potassium Citrate (by Strides Pharma Inc.)
- Potassium Citrate (by Upsher-Smith Laboratories, Llc)
- Potassium Citrate (by Xlcare Pharmaceuticals, Inc.)
- Potassium Citrate (by Zydus Lifesciences Limited)
- Potassium Citrate (by Zydus Pharmaceuticals (usa) Inc.)
- Potassium-Cit (by Eywa Pharma Inc)
- Urocit-K (by Mission Pharmacal Company)
- View full label-group details →
- Drug classes
- Anti-coagulant, Calculi Dissolution Agent
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- Prescription status
- Rx (prescription)
- CSA schedule
- Not a scheduled drug
- Pregnancy
- See Pregnancy Use Section
- Lactation
- See Lactation Use Section
- Marketed in the U.S.
- Since 2025
- Label revision date
- September 12, 2025
- Manufacturer
- REMEDYREPACK INC.
- Registration number
- ANDA214420
- NDC root
- 70518-4477
- FDA Insert
- Prescribing information, PDF file
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
If you are a consumer or patient please visit this version.
Drug Overview
Potassium citrate is a medication that comes in the form of extended-release tablets, which are a citrate salt of potassium. It is primarily used to help manage certain kidney conditions, including renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis (a type of kidney stone), and uric acid lithiasis (uric acid stones) with or without calcium stones.
By increasing the levels of citrate in your urine, potassium citrate helps to prevent the formation of these types of stones, making it an important treatment option for individuals prone to kidney stones. The tablets are taken orally and are available in different strengths, providing flexibility based on your specific needs.
Uses
Potassium citrate extended-release tablets are used to help manage certain kidney-related conditions. If you have renal tubular acidosis (RTA) with calcium stones, this medication can assist in your treatment. It is also effective for hypocitraturic calcium oxalate nephrolithiasis, which refers to the formation of kidney stones due to low levels of citrate in the urine, regardless of the underlying cause. Additionally, it can be used for uric acid lithiasis, which involves the presence of uric acid stones, with or without calcium stones.
This medication is designed to help maintain your kidney health and prevent the formation of these types of stones. Always consult with your healthcare provider to ensure it’s the right choice for your specific condition.
Dosage and Administration
If you have been diagnosed with severe hypocitraturia (a condition where your urine has low levels of citrate), your treatment will start with a daily dose of 60 mEq (milliequivalents). You can take this as 30 mEq twice a day or 20 mEq three times a day. It's important to take your doses with meals, within 30 minutes after eating, or during a bedtime snack to help your body absorb the medication effectively.
For those with mild to moderate hypocitraturia (where your urine has slightly higher citrate levels), the initial daily dose will be 30 mEq. This can be taken as 15 mEq twice a day or 10 mEq three times a day, also with meals, within 30 minutes after meals, or at bedtime. Following these guidelines will help ensure that you get the most benefit from your treatment.
What to Avoid
It’s important to be aware of certain conditions that may prevent you from safely using this medication. You should not take it if you have high potassium levels (hyperkalemia) or conditions that could lead to this, such as chronic kidney failure, uncontrolled diabetes, or severe dehydration. Additionally, if you have issues that affect how food moves through your digestive system—like delayed gastric emptying, esophageal compression, or intestinal blockages—you should avoid this medication.
You should also refrain from using it if you have peptic ulcer disease, an active urinary tract infection, or significant kidney problems (with a glomerular filtration rate of less than 0.7 ml/kg/min). Always consult your healthcare provider if you have any of these conditions to ensure your safety.
Side Effects
You may experience some common side effects while taking potassium citrate, including minor gastrointestinal issues like abdominal discomfort, nausea, vomiting, diarrhea, or loose bowel movements. However, there are also serious side effects to be aware of. One significant risk is hyperkalemia, which is an elevated level of potassium in the blood that can lead to cardiac arrest. This condition can develop quickly and may not show symptoms, so it’s crucial to avoid potassium citrate if you have chronic kidney problems or other conditions that affect potassium excretion.
If you experience severe vomiting, abdominal pain, or gastrointestinal bleeding, you should stop taking potassium citrate immediately and seek medical attention to rule out serious issues like bowel perforation or obstruction. Additionally, if you have conditions such as peptic ulcer disease, active urinary tract infections, or renal insufficiency, you should discuss these with your healthcare provider before starting treatment.
Warnings and Precautions
You should be aware of some important warnings when using potassium citrate. If you have kidney problems or conditions that affect how your body gets rid of potassium, such as severe heart issues, using potassium citrate can lead to dangerously high potassium levels (hyperkalemia), which can cause serious heart problems. Additionally, if you experience severe vomiting, abdominal pain, or gastrointestinal bleeding, stop taking potassium citrate right away and consult your doctor to rule out any serious issues like bowel perforation or obstruction.
It's crucial to monitor your health while using this medication. If you notice any severe symptoms, seek medical attention immediately. Always keep your healthcare provider informed about your health conditions to ensure safe use of potassium citrate.
Overdose
If you suspect an overdose, it’s important to be aware of the potential for a condition called hyperkalemia, which is an elevated level of potassium in the blood. This can happen quickly and may not show any symptoms at first, but it can lead to serious issues like cardiac arrest (when the heart stops beating). Signs of hyperkalemia can include irregular heartbeats or changes in your body's electrolyte levels. If you notice any unusual symptoms, seek medical help immediately.
To manage hyperkalemia, healthcare providers will closely monitor your heart and electrolyte levels. They may recommend stopping any medications that contain potassium and avoiding foods high in potassium. In some cases, treatments like intravenous calcium gluconate, dextrose with insulin, or sodium bicarbonate may be used to help lower potassium levels. For severe cases, procedures like hemodialysis or peritoneal dialysis might be necessary. It’s crucial to address this condition carefully, especially if you are taking digitalis, as lowering potassium levels too quickly can lead to digitalis toxicity, which can be dangerous. Always consult a healthcare professional if you have concerns about an overdose or related symptoms.
Pregnancy Use
If you are pregnant or planning to become pregnant, it's important to be cautious with medications. Currently, there have been no animal studies to assess the effects of potassium citrate on reproduction or fetal development. This means that we do not know if potassium citrate could harm your baby or affect your ability to have children.
Potassium citrate should only be used during pregnancy if it is clearly necessary. Always consult with your healthcare provider to discuss the potential risks and benefits before taking any medication while pregnant. Your health and the health of your baby are the top priority.
Lactation Use
While there haven't been any studies on animal reproduction regarding potassium citrate, it's important to be cautious. Currently, we don't know if potassium citrate can harm a developing fetus or affect reproductive ability when given to pregnant women. Therefore, if you are pregnant and considering potassium citrate, it should only be used if absolutely necessary and under the guidance of your healthcare provider.
If you are breastfeeding, it's essential to discuss any medications with your doctor to ensure they are safe for you and your baby. Always prioritize your health and your child's well-being when making decisions about medication use during this time.
Pediatric Use
When considering this medication for your child, it's important to know that its safety and effectiveness in children have not been established. This means that there isn't enough research to confirm how well it works or how safe it is for kids. Always consult with your child's healthcare provider to discuss any concerns and to determine the best treatment options for their specific needs.
Geriatric Use
When it comes to using this medication in older adults, there is no specific information available about dosage adjustments or safety concerns. This means that if you or a loved one is an older adult, it’s important to consult with a healthcare provider for personalized advice. They can help determine the best approach based on individual health needs and any other medications being taken. Always prioritize open communication with your healthcare team to ensure safe and effective treatment.
Renal Impairment
If you have kidney problems, it's important to be cautious with potassium citrate, as it can lead to a serious condition called hyperkalemia (high potassium levels in the blood). This can happen quickly and may not show any symptoms, but it can be life-threatening and even cause cardiac arrest (a sudden stop of the heart). Therefore, if you have chronic kidney failure or any other condition that affects your ability to excrete potassium, such as severe heart damage or heart failure, you should avoid using potassium citrate altogether. Always consult your healthcare provider for guidance tailored to your specific situation.
Hepatic Impairment
If you have liver problems, it's important to know that there are no specific guidelines or dosage adjustments mentioned for your condition in the available information. This means that the standard recommendations apply, but you should always consult your healthcare provider for personalized advice. They can help monitor your liver function and determine the best course of action for your treatment.
Make sure to keep your doctor informed about your liver health, as they may need to conduct regular tests to ensure your safety while using any medication. Your well-being is a priority, so don't hesitate to ask questions or express any concerns you may have.
Drug Interactions
It's important to talk to your healthcare provider about any medications you are taking, as some can interact with each other in ways that may be harmful. For example, if you are using potassium-sparing diuretics, combining them with certain medications can lead to dangerously high levels of potassium in your blood, a condition known as hyperkalemia. Additionally, drugs that slow down how quickly food moves through your digestive system, like some anticholinergics, can increase irritation in your stomach when taken with potassium salts.
You should also be cautious if you are taking renin-angiotensin-aldosterone inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs), as these can also raise your risk of hyperkalemia. Always keep your healthcare provider informed about all the medications and supplements you are using to ensure your safety and well-being.
Storage and Handling
To ensure the best performance of your product, store it in a cool, dry place at a temperature between 20°C to 25°C (68°F to 77°F). It’s acceptable for the temperature to occasionally range from 15°C to 30°C (59°F to 86°F), but try to keep it as close to the recommended range as possible. Always keep the product in a tight container to protect it from moisture and contamination.
When handling the product, make sure to do so with clean hands and in a clean environment to maintain its integrity. Proper storage and careful handling are essential for safety and effectiveness, so please follow these guidelines closely.
Additional Information
No further information is available.
FAQ
What is Potassium Citrate?
Potassium citrate is a citrate salt of potassium, available in extended-release tablet form.
What are the indications for using Potassium Citrate?
Potassium citrate is indicated for managing renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis.
What are the common side effects of Potassium Citrate?
Common side effects include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, and nausea.
What serious side effects should I be aware of?
Serious side effects include hyperkalemia, which can lead to cardiac arrest, and gastrointestinal lesions, which may require immediate discontinuation of the drug.
Are there any contraindications for Potassium Citrate?
Yes, contraindications include hyperkalemia, gastrointestinal obstruction, peptic ulcer disease, active urinary tract infection, and renal insufficiency.
What should I do if I experience severe vomiting or abdominal pain while taking Potassium Citrate?
You should discontinue Potassium Citrate immediately and consult your doctor to investigate the possibility of bowel perforation or obstruction.
Can Potassium Citrate be used during pregnancy?
Potassium citrate should only be given to a pregnant woman if clearly needed, as its effects on fetal harm are not well established.
What is the recommended dosage for severe hypocitraturia?
For severe hypocitraturia, therapy should start at 60 mEq per day, with doses of 30 mEq twice daily or 20 mEq three times daily.
How should Potassium Citrate be stored?
Store Potassium Citrate at 20°C to 25°C (68°F to 77°F) in a tight container, with excursions permitted between 15°C to 30°C (59°F to 86°F).
Packaging Info
The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.
Details | ||||
|---|---|---|---|---|
| Tablet, Extended Release | 10 meq | ||
Product details Regulatory status — Marketed All current FDA data sets list this NDC as actively marketed. FDA record dates for this NDC:
Active ingredients
Inactive ingredients
| ||||
FDA Insert (PDF)
This is the full prescribing document for Potassium Citrate, submitted to the U.S. Food and Drug Administration (FDA). It contains official information for healthcare providers, including how to use the medication, possible side effects, and safety warnings.
Description
Potassium citrate extended-release tablets are a citrate salt of potassium with the empirical formula K3C6H5O7 • H2O. These tablets are off white to tan yellowish, oral wax-matrix formulations. Each tablet contains 5 mEq (540 mg), 10 mEq (1080 mg), or 15 mEq (1620 mg) of potassium citrate. Inactive ingredients include carnauba wax, silicon dioxide, and magnesium stearate.
Uses and Indications
Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) associated with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis, with or without calcium stones.
There are no teratogenic or nonteratogenic effects associated with the use of this medication.
Dosage and Administration
For patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq per day. This can be administered as 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals, within 30 minutes after meals, or at bedtime.
In cases of mild to moderate hypocitraturia (urinary citrate > 150 mg/day), therapy should commence at a dosage of 30 mEq per day. This may be given as 15 mEq two times per day or 10 mEq three times per day, also to be taken with meals, within 30 minutes after meals, or at bedtime.
It is essential to adhere to these dosing schedules to optimize therapeutic outcomes and ensure patient safety.
Contraindications
Use of this product is contraindicated in the following situations:
Patients with hyperkalemia or conditions predisposing to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown, due to the risk of exacerbating elevated potassium levels.
Patients with gastrointestinal conditions that may cause arrest or delay in tablet passage, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture, as these conditions may hinder proper absorption.
Patients with peptic ulcer disease, as the product may exacerbate gastrointestinal irritation.
Patients with active urinary tract infections, due to the potential for worsening the infection.
Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min, as this may lead to accumulation of the product and increased risk of adverse effects.
Warnings and Precautions
Patients receiving potassium citrate should be closely monitored for the development of hyperkalemia, particularly in those with compromised renal function or conditions that impair potassium excretion, such as severe myocardial damage or heart failure. The administration of potassium citrate in these populations poses a significant risk of hyperkalemia, which can lead to cardiac arrest. It is crucial to recognize that hyperkalemia may develop rapidly and can be asymptomatic, necessitating vigilant monitoring of potassium levels in at-risk patients (5.1).
In the event of severe gastrointestinal symptoms, including vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately. Healthcare professionals must investigate the potential for bowel perforation or obstruction in such cases to prevent serious complications (5.2).
No additional general precautions or specific laboratory tests have been identified for the safe use of potassium citrate. However, healthcare providers should remain alert to the signs and symptoms that warrant immediate medical evaluation and intervention.
Side Effects
Patients may experience a range of adverse reactions associated with potassium citrate administration. Common adverse reactions include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, and nausea.
Serious adverse reactions can occur, particularly in patients with impaired mechanisms for excreting potassium. Hyperkalemia is a significant concern, as it can lead to cardiac arrest. This condition may develop rapidly and can be asymptomatic, making it potentially fatal. Therefore, the use of potassium citrate is contraindicated in patients with chronic renal failure or other conditions that impair potassium excretion, such as severe myocardial damage or heart failure.
Additionally, gastrointestinal lesions may arise, necessitating the immediate discontinuation of potassium citrate if patients experience severe vomiting, abdominal pain, or gastrointestinal bleeding. In such cases, it is crucial to investigate the possibility of bowel perforation or obstruction.
Other important considerations include the risk of hyperkalemia in patients with predisposing conditions, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown. Furthermore, potassium citrate should be used with caution in patients who may experience delays in tablet passage through the gastrointestinal tract, including those with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture. Patients with peptic ulcer disease, active urinary tract infections, or renal insufficiency (with a glomerular filtration rate of less than 0.7 ml/kg/min) are also at increased risk for adverse reactions.
Drug Interactions
Concomitant administration of potassium-sparing diuretics is contraindicated due to the potential for severe hyperkalemia. It is advisable to avoid the use of these agents in conjunction with potassium supplements or medications that may increase potassium levels.
Drugs that slow gastrointestinal transit time, such as anticholinergics, may exacerbate gastrointestinal irritation when used with potassium salts. Caution is recommended when these agents are prescribed together.
For patients receiving renin-angiotensin-aldosterone inhibitors, it is essential to monitor serum potassium levels regularly to detect any signs of hyperkalemia.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may also contribute to elevated potassium levels. Therefore, monitoring for hyperkalemia is advised when these medications are used concurrently with potassium-affecting agents.
Packaging & NDC
The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.
Details | ||||
|---|---|---|---|---|
| Tablet, Extended Release | 10 meq | ||
Product details Regulatory status — Marketed All current FDA data sets list this NDC as actively marketed. FDA record dates for this NDC:
Active ingredients
Inactive ingredients
| ||||
Pediatric Use
Safety and effectiveness in pediatric patients have not been established. Therefore, the use of this medication in children is not recommended until further data is available to support its use in this population.
Geriatric Use
Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments or safety concerns. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy, given the lack of targeted data for this population.
Pregnancy
Pregnant patients should be aware that animal reproduction studies have not been conducted with potassium citrate. Therefore, it is not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Given the lack of data, potassium citrate should be prescribed to pregnant women only if clearly needed, weighing the potential benefits against any unknown risks to fetal outcomes. Healthcare professionals are advised to exercise caution and consider alternative treatments when appropriate.
Lactation
There are no available data from animal reproduction studies regarding the excretion of potassium citrate in human breast milk. The effects of potassium citrate on breastfed infants are not well characterized, and it is unknown whether potassium citrate can cause harm to a nursing infant or affect reproductive capacity.
Potassium citrate should be administered to lactating mothers only if clearly needed, taking into consideration the potential risks and benefits.
Renal Impairment
Patients with impaired mechanisms for excreting potassium are at an increased risk of hyperkalemia when administered potassium citrate. This condition can lead to cardiac arrest and may develop rapidly, often without symptoms. Therefore, the use of potassium citrate is contraindicated in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure. Careful consideration and monitoring are essential in these populations to prevent potentially fatal outcomes.
Hepatic Impairment
Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.
Overdosage
In cases of overdosage, hyperkalemia may develop rapidly, particularly in patients with compromised mechanisms for potassium excretion. This condition can be asymptomatic initially but poses a significant risk of cardiac arrest if not addressed promptly.
Management of Hyperkalemia The management of hyperkalemia necessitates close monitoring for arrhythmias and electrolyte imbalances. It is essential to eliminate any medications that contain potassium, as well as potassium-sparing agents, to mitigate the risk of exacerbating hyperkalemia. Additionally, dietary modifications should be implemented, including the removal of foods high in potassium.
In instances where the patient is at low or no risk of developing digitalis toxicity, intravenous calcium gluconate may be administered as part of the treatment protocol. Another effective treatment option involves the administration of a 10% dextrose solution at a rate of 300-500 mL/hr, combined with 10-20 units of crystalline insulin per 1,000 mL, to help lower potassium levels.
If acidosis is present alongside hyperkalemia, the correction of acidosis with intravenous sodium bicarbonate is recommended. In severe cases of hyperkalemia, more aggressive interventions such as hemodialysis or peritoneal dialysis may be required to restore normal potassium levels.
It is crucial to note that lowering potassium levels too rapidly in patients who are taking digitalis can precipitate digitalis toxicity, necessitating careful management and monitoring throughout the treatment process.
Nonclinical Toxicology
Animal reproduction studies have not been conducted to evaluate the teratogenic potential of potassium citrate. Consequently, it remains unknown whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Therefore, potassium citrate should be administered to pregnant women only if clearly needed.
Regarding non-teratogenic effects, the normal potassium ion concentration in human milk is approximately 13 mEq/L. However, it is not established whether potassium citrate influences this concentration. As such, potassium citrate should be given to breastfeeding women only if clearly needed.
No specific details regarding nonclinical toxicology or animal pharmacology and toxicology are available in the insert.
Postmarketing Experience
No postmarketing experience details are available in the provided data.
Patient Counseling
Advise patients to take each dose of the medication without crushing, chewing, or sucking the tablet to ensure proper absorption and effectiveness. It is important for patients to take this medicine only as directed, particularly if they are also using diuretics and digitalis preparations, as this can affect their treatment regimen.
Patients should be instructed to consult their doctor if they experience any difficulty swallowing the tablets or if they feel that the tablet is sticking in their throat. Additionally, patients must be made aware of the importance of reporting any signs of gastrointestinal bleeding, such as tarry stools, to their doctor immediately.
Inform patients that their healthcare provider will conduct regular blood tests and electrocardiograms to monitor their safety while on this medication. This ongoing assessment is crucial for ensuring the patient's well-being during treatment.
Storage and Handling
The product is supplied in a tight container to ensure stability and integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). Proper storage conditions are essential to maintain the product's efficacy and safety.
Additional Clinical Information
No further data are available.
FDA Insert (PDF)
This document is the official FDA-approved prescribing information for Potassium Citrate as submitted by REMEDYREPACK INC.. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.